More recently, the term aHUS has been used to refer only to HUS involving complement abnormalities, such as complement factor H, component 3 (C3), and other elements [41], and is classified etiologically as a complement-mediated TMA. The gene discussed is CFH; the disease is hemolytic-uremic syndrome.